Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indium-111-DOTA-labetuzumab-IRDye800CW
- Development stage
- Phase 2
- Lead developer
- Radboud University Medical Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Indium-111-DOTA-labetuzumab-IRDye800CW is an investigational, dual-labeled **CEA-targeted imaging conjugate** developed by Radboud University Medical Center for image-guided cytoreductive surgery in colorectal cancer peritoneal metastases. It consists of the humanized anti-carcinoembryonic antigen antibody labetuzumab conjugated to the DOTA chelator carrying indium-111 for SPECT/CT and gamma-probe detection, plus the near-infrared fluorophore IRDye800CW for intraoperative fluorescence imaging. The agent binds carcinoembryonic antigen-related cell adhesion molecule 5 on colorectal cancer cells and is intended to improve preoperative staging and intraoperative identification of tumor deposits rather than directly treat the cancer. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03699332?tab=researcher))
- Other names
- [111In]In-DOTA-labetuzumab-IRDye800CW111In-DOTA-labetuzumab-IRDye800CW
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on indium-111-DOTA-labetuzumab-IRDye800CW.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indium-111-DOTA-labetuzumab-IRDye800CW.